Executive Summary

Valued at 7.2 USD Billion in 2025, the Liquid Biopsy Technologies Market is forecast to reach 28.9 USD Billion by 2035, expanding at a CAGR of 14.8%.

Adoption is pulled forward by oncologists’ need for tissue-free molecular profiling ahead of targeted and immunotherapy selection, and by regulatory frameworks such as the EU’s Medical Device Regulation (EU) 2017/745, which sets the conformity assessment and post-market surveillance bar that assay developers must clear to reach European clinics.

North America held 43.0% of the market in 2025, supported by established reimbursement coding for molecular diagnostics. Circulating Tumor DNA led biomarker demand, and Cancer Screening was the leading application, reflecting broad uptake of blood-based testing ahead of confirmatory imaging.

Reimbursement uncertainty for newer applications such as multi-cancer early detection continues to slow payer coverage decisions outside markets with established coding pathways. Competition centers on assay sensitivity, regulatory clearance breadth and reimbursement-code access rather than list price.

Key Takeaways

• Valued at 7.2 USD Billion in 2025, reaching 28.9 USD Billion by 2035 at a 14.8% CAGR.
• Circulating Tumor DNA leads biomarker-type demand.
• Multi-Cancer Early Detection is the fastest-growing screening application.
• North America held 43.0% of the market in 2025.
• EU MDR 2017/745 compliance is accelerating therapy-selection testing adoption.
• Reimbursement uncertainty limits payer coverage for multi-cancer early detection.

Market Definition and Scope

The Liquid Biopsy Technologies Market covers assays and platforms that detect circulating tumor DNA, circulating tumor cells, cell-free RNA, and extracellular vesicles from blood or other body fluids for cancer screening, therapy selection, treatment monitoring, and recurrence surveillance, serving hospital and reference laboratories, oncology clinics, and pharmaceutical sponsors running companion-diagnostic and minimal residual disease programs.

It excludes tissue-based histopathology, standalone next-generation sequencing panels run on solid-tumor biopsy specimens, and cell-free DNA testing performed for non-oncology indications such as prenatal screening.

Growth Drivers and Restraints

Companion-Diagnostic Requirements Are Pulling Blood-Based Testing Into Standard Oncology Workflows

Targeted-therapy and immunotherapy regimens require molecular confirmation before prescribing, and tissue rebiopsy is not always feasible in advanced-stage patients, so oncologists increasingly order circulating tumor DNA panels at diagnosis and at progression. The European Union’s Medical Device Regulation (EU) 2017/745 has raised the conformity-assessment and clinical-evidence bar for these assays, pushing developers toward larger validation studies before CE marking. In the United States, the FDA’s Breakthrough Device Designation pathway has shortened review timelines for several ctDNA-based companion diagnostics, reinforcing label expansion into Therapy Selection ahead of tissue-based alternatives in eligible indications where blood-based testing is becoming the standard of care.

Minimal Residual Disease Monitoring Is Reshaping Post-Treatment Surveillance Protocols

Oncologists managing resected colorectal, breast and lung cancers are adopting serial ctDNA testing to detect molecular relapse ahead of radiographic recurrence, shifting surveillance volume toward the Recurrence Monitoring application. Coverage decisions under the CMS MolDX program for molecular diagnostics have extended reimbursement to tumor-informed MRD assays in several indications, and inclusion of MRD-guided escalation in NCCN guideline updates is steering adjuvant-therapy decisions toward blood-based confirmation rather than imaging alone. This is concentrating demand, and consumable pull-through, in Tumor-Informed MRD Testing among reference laboratories serving oncology networks with established market access.

Multi-Cancer Early Detection Is Extending Circulating Tumor DNA Use Into Asymptomatic Screening

Screening programs are moving beyond single-cancer assays toward panels that scan for multiple tumor types from one blood draw, widening the addressable population beyond diagnosed patients. Pilot and registry studies registered on ClinicalTrials.gov are generating the outcomes evidence payers require before covering asymptomatic screening, and FDA engagement on a regulatory framework for this device class is clarifying the approval pathway for developers. North America’s established reimbursement infrastructure positions it to absorb this expansion first, reinforcing Cancer Screening as the leading application by volume.

EU MDR Recertification Is Raising the Cost of Sustaining Legacy Assays

Assays cleared under the EU’s prior medical device directives must be revalidated under Regulation (EU) 2017/745, requiring expanded clinical-performance documentation, a quality-management system and post-market surveillance reporting before recertification. Smaller diagnostic developers face a higher relative cost burden than diversified in-vitro diagnostics manufacturers, and some are narrowing their European test menus rather than fund full recertification, concentrating supply among larger platform providers with broader HTA engagement.

Clinical-Utility Evidence Requirements Are Slowing Guideline-Driven Adoption

Reimbursement for newer applications such as multi-cancer early detection and tumor-naive MRD testing depends on prospective outcomes data that NCCN and payer technology-assessment committees require before a favorable coverage decision, and generating that evidence takes multi-year registry follow-up measured in patient-years. Community oncology practices without in-house molecular tumor boards are slower to adopt these assays than academic centers, delaying volume growth outside established markets such as North America and parts of Europe.

Market Trends

Minimal Residual Disease Testing Is Moving From Research Use Into Adjuvant Treatment Decisions

Serial ctDNA monitoring after curative-intent surgery is shifting from a research tool into a factor guiding adjuvant chemotherapy decisions. NCCN guideline updates now reference MRD status in select tumor types, and the CMS MolDX program has extended coverage to tumor-informed assays. Reference laboratories and academic oncology networks are the primary adopters, concentrating demand in Tumor-Informed MRD Testing within Recurrence Monitoring through 2025-2035 as post-surgical surveillance incorporates blood-based confirmation.

Multi-Cancer Early Detection Panels Are Advancing From Pilot Screening Toward Broader Population Use

Blood-based panels designed to flag multiple tumor types from a single draw are progressing from pilot cohorts toward the outcomes evidence payers and screening guideline bodies require before recommending routine use. FDA engagement on a dedicated regulatory framework, alongside registry studies listed on ClinicalTrials.gov, is narrowing that evidence gap. Because screening reaches asymptomatic individuals rather than diagnosed patients, adoption depends on payer willingness to fund testing ahead of confirmed disease, positioning Cancer Screening to absorb a growing share of blood draws through 2035.

Methylation and Fragmentomic Analysis Is Extending Detection Beyond Mutation-Only Panels

Assay developers are layering methylation and fragment-pattern analysis onto mutation-based ctDNA panels to improve sensitivity for early-stage tumors that shed too little DNA for mutation calling alone. Peer-reviewed clinical-endpoint studies have linked these signals to tumor origin and stage. Laboratories serving early-detection programs are the primary adopters, and the approach is expected to lift sensitivity across Cancer Screening and Treatment Monitoring as panels combine multiple analyte classes rather than relying on DNA mutations alone.

Regional Analysis

North America held 43.0% of the liquid biopsy technologies market in 2025, the largest of the three regions covered here. The region’s scale traces to a specific regulatory event: the FDA’s July 2024 approval of Guardant Health’s Shield blood test for a primary colorectal cancer screening indication, the first blood draw to carry that label rather than a diagnostic-aid designation. A CMS coverage decision followed, assigning oncologists and primary-care physicians a CPT billing code that private payers then mirrored into their own reimbursement schedules. That approval-to-coverage sequence, not patient demand alone, is what converts a validated assay into market access and ordered volume across US health systems.

Europe accounted for 22.0% of the market in 2025. Demand here is shaped less by single approvals than by public-system trial infrastructure: NHS England’s Galleri programme, run with GRAIL across primary care sites in England, is testing whether a multi-cancer early detection blood test can earn a national coverage decision through health technology assessment rather than remain a specialty referral tool. Manufacturers separately absorb the cost of EU MDR recertification for existing in vitro diagnostic assays, a compliance burden that favours companies with the regulatory staff to refile rather than smaller entrants chasing the same market access.

Asia Pacific took a 30.0% share in 2025, split across markets moving at different regulatory speeds. China’s National Healthcare Security Administration has begun folding next-generation sequencing oncology panels into provincial volume-based procurement rounds, compressing per-test pricing while widening market access beyond tier-one-city hospitals. Japan’s reimbursement listing process under PMDA remains slower and more selective, so uptake there still concentrates in university hospitals running companion-diagnostic panels tied to a specific targeted-therapy standard of care rather than broad screening programmes.

Segment Analysis

By Biomarker Type

• Circulating Tumor DNA (largest) – Fragmented tumor-derived DNA shed into blood plasma, analyzed via PCR or sequencing to detect mutations without a tissue biopsy
• Mutation Analysis

• Single Nucleotide Variants
• Insertions/Deletions

• Methylation Analysis
• Copy Number Variation Analysis
• Fragmentomics
• Circulating Tumor Cells – Intact cancer cells that detach from a primary or metastatic tumor and enter the bloodstream, captured and counted to assess disease status
• CTC Enumeration

• EpCAM-Based Capture
• Size-Based Filtration

• CTC Molecular Characterization
• CTC Cluster Analysis
• Cell-Free RNA – Extracellular RNA fragments, including messenger and microRNA, circulating in blood and used as gene expression markers of tumor activity

• Messenger RNA (mRNA)
• MicroRNA (miRNA)
• Long Non-Coding RNA (lncRNA)
• Extracellular Vesicles & Exosomes – Membrane-bound particles released by cells that carry proteins, lipids, and nucleic acids reflecting their tissue of origin, isolated for molecular profiling

• Exosomal RNA
• Exosomal DNA
• Exosomal Protein
• Other Biomarkers – Additional circulating analytes such as tumor-educated platelets or proteins that do not fall under DNA, cell, RNA, or vesicle categories

• Circulating Tumor Proteins
• Tumor-Educated Platelets
• Cell-Free DNA (Non-Tumor)

Circulating tumor DNA is the leading biomarker class in 2025, ahead of circulating tumor cells, cell-free RNA and extracellular vesicles. ctDNA assays pair with standard PCR and next-generation sequencing workflows already installed in oncology reference labs, so a new panel is a protocol change rather than a capital purchase. Fragment size and mutation-calling algorithms have also matured furthest for ctDNA, giving it the deepest base of peer-reviewed mutation and methylation data to support a therapy-selection or monitoring claim. Extracellular vesicles and exosomes are expanding fastest, pulled by proteomic and RNA cargo that ctDNA cannot capture, since an intact vesicle carries signal on tumor origin and microenvironment that fragmented DNA discards. Assay developers are adding exosomal RNA and protein panels alongside existing ctDNA tests rather than replacing them, since mutation calling alone can leave therapy selection ambiguous in cases with low tumor fraction.

By Application

• Cancer Screening (largest) – Testing asymptomatic or average-risk individuals for circulating tumor markers to detect malignancy before clinical symptoms or imaging findings appear

• Single-Cancer Early Detection
• Multi-Cancer Early Detection (MCED)
• Therapy Selection – Profiling a patient’s tumor-derived DNA or cells to match them with targeted drugs, immunotherapies, or clinical trials suited to their molecular profile

• Targeted Therapy Selection
• Immunotherapy Selection
• Treatment Monitoring – Serial blood sampling during active therapy to track tumor burden, detect emerging drug resistance mutations, and inform dosing or regimen changes

• Therapy Response Monitoring
• Resistance Mutation Monitoring
• Recurrence Monitoring – Periodic post-treatment surveillance for residual or returning disease by detecting minimal residual disease signals ahead of radiographic relapse
• Minimal Residual Disease (MRD) Monitoring

• Tumor-Informed MRD Testing
• Tumor-Naive (Tumor-Agnostic) MRD Testing
• Post-Treatment Surveillance

Cancer screening is the leading application in 2025, ahead of therapy selection, treatment monitoring and recurrence monitoring. Screening carries the largest addressable population, since it targets asymptomatic and average-risk adults rather than an already-diagnosed patient pool, and multi-cancer early detection panels have given primary care a single blood draw to order instead of a battery of imaging referrals. Recurrence monitoring, particularly minimal residual disease testing, is growing fastest. Oncologists are using serial MRD results to decide whether a patient needs adjuvant chemotherapy at all, turning a surveillance test into a treatment-selection tool rather than a follow-up formality. That shift pulls volume away from fixed-interval imaging surveillance and toward blood draws scheduled around treatment decision points.

Competitive Landscape

The liquid biopsy technologies market is led by a group of established diagnostics, sequencing and instrumentation companies rather than a single dominant supplier: Guardant Health, F. Hoffmann-La Roche, Illumina, Thermo Fisher Scientific, QIAGEN, Exact Sciences, Natera, NeoGenomics, Bio-Rad Laboratories and Sysmex Corporation. Competition centers on clinical evidence and label breadth, since a test’s value rests on the strength of the peer-reviewed and regulatory data behind its screening, therapy-selection or monitoring claim. Regulatory approval status compounds that advantage: a company holding an FDA-approved primary screening claim, rather than a laboratory-developed test running under CLIA alone, can be ordered and billed more broadly. Reimbursement coverage and CPT coding determine which of those approved tests actually get used at scale, and sequencing-platform ownership adds a further lock-in layer, since Illumina and Thermo Fisher supply the instruments that competitors’ assay developers depend on to run their own panels. KOL relationships and guideline inclusion, through bodies such as NCCN and ASCO, shape which panel a tumor board defaults to when several are approved for the same indication.

Strategic Outlook

Multi-cancer early detection (MCED) is the clearest whitespace through 2035: one blood draw covering several tumor types under a single indication, ordered the way a lipid panel is today rather than as a separate assay per cancer. Realizing it depends on payers extending a coverage decision like the NHS Galleri pathway and the pending CMS reimbursement determination beyond single-cancer assays, since Medicare inclusion and CPT coding typically set the template commercial payers follow.

By 2035, ordering is expected to shift from tissue-first workflows toward blood-first triage, with tissue biopsy reserved for confirmation and guideline inclusion following FDA clearance rather than preceding it. Instrument makers that also sell assays hold the advantage: consumable pull-through on an installed sequencing base, billed per patient-year, compounds faster than any single test launch, and this class of device carries less EU MDR recertification exposure in Europe or PMDA reform risk in Japan than single-use kits.

Liquid Biopsy Technologies Market Report Scope